09688

16.3905.53%
YD

Ying Du

Founder, Chairperson & CEO

Dr. Ying Du, Ph.D., also known as Samantha, serves as Founding Managing Director at Quan Capital. She served as Venture Partner at Sequoia Capital China. Dr. Du serves as an adjunct professor at Fudan University, School of Pharmacy. She serves as a Board Member at BGI tech and Beta pharma. Dr. Du served as Director at Betta Pharmaceuticals Co., Ltd. She served as Managing Director at Sequoia Capital China and was responsible for healthcare investment. Dr. Du joined Sequoia Capital China in 2012. She serves as Chief Technology Officer of Hehuang Traditional Chinese Medicine Technology Co., Ltd. Dr. Du serves as Partner of Venture Capital of Hongcai Capital Investment Management (Tianjin) Co., Ltd. She serves as General Partner at Zai Venture Fund I, L.P. She founded ZAI Lab. Dr. Du has been the Chairperson and Chief Executive Officer at ZAI Lab Limited (formerly ZAI Laboratory, Inc.) since 2014. She is employed at ZAI Lab Limited. Dr. Du served as a Director of China Animal Healthcare Ltd. since February 20, 2014 until March 17, 2016. Dr. Du Founded Hutchison MediPharma Ltd. in 2002 and served as its Chief Executive Officer. She was also the co-Founder at Hutchison Chi-Med. Dr. Du served as the Chief Scientific Officer of Chi-Med of Hutchison China MediTech Ltd. She served as Director of JHL Biotech, Inc. She has been a successful drug developer, entrepreneur, Investor and an overall industry leader in China. Dr. Du began her career with Pfizer in the US where she was responsible for the company’s global metabolic licensing program and was also involved in the development of multiple early and late-stage products, including two global blockbusters. She is an active advisor on healthcare and biotech issues for various government agencies and research institutions in China. Dr. Du joined Hutchison Whampoa in 2001 to lead the global pharmaceutical R&D and Health Care Investment activities in it. She started her research career at Pfizer's Global R&D center in Connecticut and led teams that delivered multiple INDs and NDAs in several Therapeutic Areas. Dr. Du served at Pfizer's global strategic operation division in charge of global Licensing and related merge & acquisition activities for metabolic diseases. She has been recognized with awards such as 2016 BayHelix Person of the Year, China Entrepreneur of the Year 2008 and FierceBiotech’s Top 12 Women in Biopharma 2015. Dr. Du is a recipient of Shanghai's 2010 Magnolia award and recipient of Shanghai's thousand talent program. She holds a Ph.D. in Biochemistry from the University of Cincinnati and a B.S. in Molecular Biology from Jilin University, China.

Positions